Why Aspirin Acts as an Antiplatelet Agent
Aspirin irreversibly inhibits the enzyme cyclooxygenase-1 (COX-1) in platelets by acetylating a serine residue at position 529, permanently blocking thromboxane A2 synthesis—the key amplification signal for platelet activation and aggregation. 1
Molecular Mechanism of Action
Aspirin selectively acetylates the hydroxyl group of serine-529 (Ser529) within the polypeptide chain of platelet prostaglandin H-synthase (PGH-synthase), also known as COX-1. 1 This acetylation occurs through a covalent modification that permanently inactivates the enzyme's cyclooxygenase activity, while leaving its hydroperoxidase activity intact. 1
The Arachidonic Acid Pathway
- COX-1 normally converts arachidonic acid (released from platelet membrane phospholipids) into prostaglandin H2 (PGH2), which is then converted to thromboxane A2 (TXA2). 1, 2
- TXA2 is a potent vasoconstrictor and platelet aggregator that provides a critical amplification mechanism for platelet activation in response to various agonists. 1, 3
- By blocking COX-1, aspirin prevents TXA2 synthesis, thereby inhibiting this amplification pathway and reducing platelet aggregation. 4, 5
Unique Pharmacological Properties
"Hit-and-Run" Mechanism
Aspirin functions through an ideal "hit-and-run" mechanism—it permanently inactivates a platelet enzyme that cannot be resynthesized during a 24-hour dosing interval, through a short-lived active moiety with a half-life of only 15-20 minutes. 1 This design severely limits the extent and duration of extra-platelet effects while maintaining sustained antiplatelet activity. 1
Irreversibility and Duration
- The effect is irreversible throughout the entire lifespan of the platelet in circulation (7-10 days), as platelets are anucleated cells that cannot synthesize new COX-1 enzyme. 4, 2
- Despite aspirin's extremely short half-life of approximately 15-20 minutes in human circulation, its antithrombotic effect persists for 24-48 hours with once-daily dosing. 1
- This prolonged effect reflects the permanent nature of platelet COX-1 inactivation and explains why aspirin can be clinically effective at very low doses (30-100 mg daily). 1
Pharmacokinetic Advantages
Aspirin is rapidly absorbed in the stomach, reaching peak concentration within 15-40 minutes, and exerts its action mainly in the portal circulation before first-pass hepatic metabolism. 4, 5 This allows preferential acetylation of platelet COX-1 before the drug is metabolized by esterases in blood and liver. 1, 4
Selectivity for Platelet COX-1
At low doses (75-100 mg daily), aspirin exhibits biochemical selectivity for platelet COX-1 over endothelial COX-2, which produces prostacyclin (PGI2)—a natural inhibitor of platelet aggregation. 1 This selectivity arises from:
- Pharmacokinetic factors: acetylation of platelet COX-1 occurs in portal blood prior to first-pass metabolism 1
- Pharmacodynamic factors: endothelial COX-2 is less sensitive to aspirin and requires higher concentrations for inhibition 1
Clinical Evidence Supporting the Mechanism
A very large database of randomized clinical trials (testing doses from 30 mg to 1500 mg daily) provides compelling evidence that aspirin's prevention of myocardial infarction and ischemic stroke is due to permanent inactivation of platelet COX-1. 1 These trials established two critical facts:
- The antithrombotic effect is saturable at doses of 75-100 mg daily, consistent with complete platelet COX-1 inactivation 1
- The effect persists with 24-48 hour dosing intervals despite the drug's 20-minute half-life, reflecting permanent enzyme inactivation 1
Important Caveat
Aspirin blocks only one amplification pathway of platelet activation; many other pathways stimulated by ADP, adrenaline, thrombin, shear stress, and high-dose collagen remain largely unaffected. 4 This explains why some patients may experience thrombotic events despite aspirin therapy, and why combination antiplatelet therapy may be necessary in high-risk situations. 4